600 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Phocas Financial Corp.

Phocas Financial Corp. purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) during the fourth quarter, Holdings Channel reports. The fund purchased 600 shares of the medical research company’s stock, valued at approximately $158,000.

A number of other large investors have also recently bought and sold shares of AMGN. Coston McIsaac & Partners bought a new stake in shares of Amgen during the 2nd quarter valued at about $27,000. EdgeRock Capital LLC acquired a new position in Amgen in the third quarter valued at approximately $25,000. Leelyn Smith LLC boosted its holdings in shares of Amgen by 80.3% during the 3rd quarter. Leelyn Smith LLC now owns 110 shares of the medical research company’s stock worth $25,000 after buying an additional 49 shares in the last quarter. Heritage Wealth Management LLC acquired a new stake in shares of Amgen during the 2nd quarter worth approximately $28,000. Finally, Lumature Wealth Partners LLC increased its stake in shares of Amgen by 51.1% in the 1st quarter. Lumature Wealth Partners LLC now owns 142 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 48 shares in the last quarter. 75.53% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Down 2.0 %

Shares of Amgen stock opened at $229.79 on Friday. The company has a market capitalization of $122.70 billion, a P/E ratio of 18.98, a price-to-earnings-growth ratio of 1.89 and a beta of 0.65. The stock has a fifty day simple moving average of $245.91 and a 200 day simple moving average of $254.81. Amgen Inc. has a 12-month low of $223.30 and a 12-month high of $296.67. The company has a current ratio of 1.41, a quick ratio of 1.10 and a debt-to-equity ratio of 10.20.

Amgen (NASDAQ:AMGN – Get Rating) last posted its quarterly earnings data on Tuesday, February 7th. The medical research company reported $4.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.04 by $0.05. The firm had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.77 billion. Amgen had a net margin of 24.89% and a return on equity of 359.47%. The business’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.36 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 17.72 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Thursday, May 18th will be given a $2.13 dividend. This represents a $8.52 dividend on an annualized basis and a yield of 3.71%. The ex-dividend date is Wednesday, May 17th. Amgen’s payout ratio is 70.36%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AMGN. Cowen cut their target price on shares of Amgen from $307.00 to $289.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 1st. Wells Fargo & Company raised shares of Amgen from an “equal weight” rating to an “overweight” rating and cut their price objective for the stock from $275.00 to $265.00 in a research report on Monday, March 13th. SVB Leerink reduced their target price on Amgen from $282.00 to $267.00 and set a “market perform” rating for the company in a research note on Thursday, February 2nd. StockNews.com assumed coverage on Amgen in a research note on Thursday. They set a “strong-buy” rating on the stock. Finally, Credit Suisse Group reduced their price objective on Amgen from $240.00 to $220.00 and set an “underperform” rating for the company in a research note on Wednesday, February 1st. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Amgen has a consensus rating of “Hold” and an average price target of $251.44.

Amgen Profile

(Get Rating)

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.